INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. Three PPAR isotypes, α, β (also called δ, FAAR and NUC1) and γ, have been cloned from Xenopus, rodents and human. PPARs regulate gene expression by binding as heterodimers with retinoid X receptors to peroxisome proliferator response elements in the promoter of genes involved in lipid metabolism (1) (2) (3) . The biological roles of PPARα and γ are relatively well understood, not least because specific ligands for these isotypes have been identified (4) . PPARα regulates genes involved in peroxisomal and mitochondrial β-oxidation as well as lipoprotein metabolism (2;5) . PPARα also suppresses apoptosis in cultured rat hepatocytes (6) and reduces inflammatory responses (7;8) . PPARγ stimulates adipogenesis, enhances insulin sensitivity, and is involved in cell cycle control and regulation of tumor growth (9) (10) (11) (12) (13) .
In contrast, the functions of PPARβ are poorly understood, due partly to its ubiquitous expression and the lack of a selective ligand. The objective of this study was to start unraveling PPARβ functions using an experimental model easy to manipulate and expressing high levels of PPARβ compared to PPARα and γ. The nervous system seemed an appropriate target for this, as PPARβ is abundantly expressed in brain from embryogenesis to adulthood, while PPARα and γ are barely detectable (14) (15) (16) (17) . The brain is the organ with the highest lipid concentration in the body, second only to adipose tissue. Brain lipids serve primarily in modifying the fluidity, structure and functions of the membranes, and both anabolic and catabolic pathways of lipid metabolism are important in brain development (18;19) . Fatty acids need to be activated to their acyl-CoA by acyl-CoA synthetases (ACS), the activities of which have been found in the brain (20;21) . Moreover, ACS1, 2 and 3 mRNAs have been analyzed in the postnatal rat brain, and the levels of ACS2 and 3 vary during its development (22) . Given the key role of ACSs in fatty acid utilization, we speculated that they could be potential targets of PPARβ in the brain.
We chose cultures of reaggregated neural cells prepared from the telencephalon of rat embryos which provide a three-dimensional network of different neural cell types that progressively acquire 4 a tissue specific pattern resembling that in the brain (23;24) . We first determined the expression pattern of PPARs during maturation of brain aggregates, providing evidence for PPARβ being the prevalent isotype. Then, using a selective activator for PPARβ, we demonstrate that the ACS2 gene is regulated by PPARβ at the transcriptional level. 5 
EXPERIMENTAL PROCEDURES
Cell culture: Reaggregated brain cell primary cultures were prepared from mechanically dissociated telencephalon of 16-day rat embryos as previously described (24) . Cultures were initiated and grown in serum-free, chemically defined medium consisting of Dulbecco's modified Eagle's medium (DMEM) with high glucose (25 mM), and supplemented with insulin (0.8 μM), triiodothyronine (30 nM), hydrocortisone-21-phosphate (20 nM), transferrin (1 μg/ml), biotin (4 μM), vitamin B12 (1 μM), linoleate (10 μM), lipoic acid (1 μM), L-carnitine (10 μM), and trace elements (listed in ref. 24) . Gentamicin sulfate (25 μg/ml) was used as antibiotic. Culture media were replenished by exchange of 5 ml of medium (of a total of 8 ml/flask) every third day until day 14, and every other day thereafter because of increased metabolic activity in the cells. The cultures were maintained under constant gyratory agitation (80 rpm), at 37 0 C and in an atmosphere of 10 % CO 2 / 90 % humidified air.
Northern blot analysis:
PPARβ mRNA was probed with the 1.32 kb BamH1 fragment of the plasmid pSG5-rPPARβ containing the coding region of the rPPARβ. 2 The different ACS mRNAs were probed with DNA fragments isolated from their respective rat cDNA containing plasmids (22) . ACS1 mRNA was probed with the 0.96 kb EcoRV fragment of the pRACS15 plasmid. ACS2 mRNA was probed with the 2 kb EcoRI fragment of the pBACS9 plasmid. ACS3 mRNA was probed with the 2.2 kb BglII/SacI fragment of the pACS3 plasmid. L27 mRNA, which was used as an internal control, was probed with the 0.22 kb XbaI/EcoRI fragment of the pKS + /L27 plasmid (25) . The above mentioned gel purified DNA fragments of PPARβ (100 ng), the three ACSs (100 ng each) and L27 (25 ng) were used as templates to synthesize [α 32 P]-dCTP labeled probes using the High Prime kit (Boehringer Mannheim). Probes were purified on Elutip-d columns according to the manufacturer's protocol (Schleicher and Schuell).
Brain cell aggregates from each flask were carefully transferred to round bottomed 14 ml Falcon tubes, washed with PBS and frozen rapidly by plunging the capped tubes into liquid nitrogen after 6 aspirating the residual amounts of PBS in the samples. AT/SM densitometer (Hirschmann) and the mRNA signals were normalized for the loading error using the L27 mRNA signal as internal control, as described previously (26) .
RNase Protection assay: [α 32 P]-UTP labeled riboprobes were transcribed in vitro with T7 RNA polymerase and RNase protection assay was carried out on 15 μg of total RNA as described previously (25 In situ hybridization: Digoxigenin labeled PPARα and β riboprobes were transcribed in vitro from linearized, gel purified plasmids using T7 RNA polymerase as described previously (17) .
Antisense probes were synthesized from the plasmids pKS Aggregates washed with PBS were embedded in tissue freezing medium (Jung, Nussloch), frozen in isopentane cooled with liquid nitrogen as described previously (24) and stored at -80 0 C until use.
Cryostat sections (12 μM thickness) were hybridized for 40 h at 58 0 C with digoxigenin labeled probes (400 ng/ml) in 5X SSC containing 50% formamide and 40 μg/ml salmon sperm DNA.
Sections were washed and the mRNAs were visualized by alkaline phosphatase staining as previously described (17) and then dehydrated, mounted and photographed on an Axiophot microscope (Carl Zeiss). The basal levels of the PPAR isotype mRNAs were different in these aggregates. PPARα mRNA was barely detectable by northern blot analysis, but was detected by RNase protection assay ( Fig.   1A ). In contrast, PPARβ mRNA was abundant and could be detected easily by northern blot analysis of total RNA (Fig. 1B) . Total cellular RNA from adult rat liver and brain was used as positive control for PPARα and β, respectively. PPARγ mRNA was not detected in the aggregates even by RT-PCR (data not shown) and therefore this isotype was not analyzed in subsequent experiments. There was also a different age-dependent pattern of expression of both PPAR isotypes.
On the one hand, the PPARβ mRNA basal level was low in undifferentiated cultures (d2, 7), increased 3-5 fold during differentiation (d14, 21, 28), remained high in differentiated (d35) and late (d42, 49) cultures (Fig. 1C) . On the other hand, the level of PPARα mRNA remained low at the four developmental stages examined (Figs. 1A and 1C inset). Thus, of the three PPARs, only the two isotypes α and β were present in the aggregates, and the levels of PPARβ increased with the onset of cell differentiation.
Cell type-specific expression of PPAR isotypes in reaggregated brain cell cultures: In order to identify the cells expressing PPARs in the aggregates, we used in situ hybridization to detect PPAR transcripts in cells ( Fig. 2A) , as well as immunohistochemical staining for cell type-specific markers to identify these cells (Fig. 2B) . The marker antigens used for immunohistochemistry were 11 MAP2 for neurons, GFAP for astrocytes and MBP for oligodendrocytes. Since MAP2 and GFAP are cytoskeletal proteins, immunostaining for these antigens is seen in the cell bodies and processes, and the in situ hybridization signal of PPAR mRNAs is cytoplasmic. Furthermore, we used thionine staining in parallel sections to visualize the nuclei in the aggregates ( Fig. 2A : q-t, 2B: i, k). At d7, a faint signal of PPARα mRNA was detected in most cells of the aggregates ( Fig. 2A: compare a with q). At d21, the signal was slightly stronger and restricted to cells with small nuclei (Fig. 2A: compare b with r) which were identified primarily as astrocytes by immunohistochemistry (Fig. 2B: compare c with d, h and l). The pattern was similar at d35 ( Fig. 2A: c) . At d49, the same cell type was positive for PPARα but with a decreased signal intensity ( Fig. 2A: d) . The sense probe for PPARα did not stain the sections ( Fig. 2A : e-h) indicating that the signal detected with the antisense probe was specific.
The in situ hybridization signal for PPARβ was higher than that for PPARα in all developmental stages of the aggregates ( 2B: compare g with d, h, and l). At d35 and d49, the pattern of expression of PPARβ mRNA was similar to that of d21, but the signal intensity was lower ( Fig. 2A: k, l) . The peripheral layer of glial cells were positive for PPARβ at all developmental stages except d7 ( Fig. 2B: d, l) . Again, the sense probe barely stained the sections ( Fig. 2A: m-p) confirming the specificity of the signal obtained for PPARβ. These results showed that PPARβ mRNA was ubiquitous in the aggregates and high in some neurons, while PPARα mRNA was mainly detected in the astrocytes.
Acyl-CoA synthetases in the aggregates: We used a three-step approach to establish whether ACSs were target genes of PPARβ in this model of the developing rat brain. Firstly, we determined the basal levels of the three ACSs in the aggregates. We then examined their cell-type specific expression pattern and lastly studied whether PPAR activators regulate their expression.
All three ACS mRNAs were easily detectable by northern blot analysis of total RNA (Fig. 3) .
ACS1 mRNA was present at a low level in the four developmental stages examined. At d21, a small but significant increase of 1.8 fold over the level at d7 was observed (t-test, p < 0.05). The basal level of ACS2 mRNA was very low at d7, but increased 5-7 fold in d21 and d35 cultures, and remained steady in the late cultures. In undifferentiated cultures, the basal level of ACS3 mRNA was the highest among the three ACSs and this increased further 2-3 fold until d49. The increase over the basal level at d7 was statistically significant for ACS2 and 3 mRNAs (t-test, p < 0.01).
The comparison of the temporal expression pattern of ACS mRNAs with that of PPARs revealed similarities between ACS1 and PPARα mRNAs on one hand and ACS2 and PPARβ mRNAs on the other hand (Figs. 1 and 3) . d). The intensity of this signal decreased at d35 and d49, but was still primarily astrocytic ( Fig. 4A: c, d). The glial cells at the periphery of the aggregates did not stain for ACS1 mRNA. ACS2 mRNA signal was higher than that of ACS1 mRNA in the aggregates, and was observed in most cells at d7
( Fig. 4A: e) . At d21, the signal was of high intensity in neurons with large nuclei, which form a broad layer in the aggregates. In the same region a signal of medium intensity was observed in other neurons, astrocytes and oligodendrocytes ( Fig. 4A: f) . In aggregates of d35 and d49, the ACS2 mRNA signal decreased in intensity (Fig. 4A: g, h) , but was present in the same cell types as 13 observed at d21. ACS3 mRNA was found in most cells of the aggregates at days 7 and 21 ( Fig. 4A: i, j) with a few cells showing a very strong signal. At d35 and d49, the ACS3 mRNA signal decreased in intensity and was observed in neurons, astrocytes and oligodendrocytes ( Fig. 4A: k, l) .
Large cells, which stained intensely at d7 and d21, were not apparent in these differentiated cultures. The peripheral layer of glial cells was positive for ACS2 and 3 mRNAs in cultures of all developmental stages except d7. No signal was observed with the sense probes for ACS1, 2 and 3 mRNAs (data not shown).
The in situ hybridization analysis of the three ACSs in d21 aggregates was compared with that of PPARβ and is shown at a higher magnification in Fig. 4B . The expression pattern of ACS2 mRNA was similar to that of PPARβ ( Fig. 4B: b, c) . This finding, taken together with their temporal pattern of expression, suggested that ACS2 might be a target gene of PPARβ.
Activation of rat PPARs in a cell based reporter gene assay: To test whether ACS2 was a
PPARβ target gene, a PPAR activator was required, that preferentially activates rPPARβ. In a recent study from our laboratory, several compounds were screened with the coactivator-dependent receptor ligand assay. Fatty acids, eicosanoids and hypolipidemic drugs were identified as ligands for Xenopus PPARs (27) . Most of the ligands identified for xPPARβ by this assay exhibited similar or greater activity towards xPPARα. As bezafibrate, which was strong on xPPARβ, was the least active on xPPARα, we tested this hypolipidemic drug on rPPARs in a reporter gene assay in HeLa cells. Transfection of the PPARα expression vector resulted in an apparent ligand independent activation of the reporter gene (Fig. 5A) , which has been observed previously in HeLa cells (31) . In cells treated with 10 and 100 μM bezafibrate, PPARα mediated transcription of the reporter gene was enhanced. In contrast, expression of PPARβ did not affect the basal activity of the reporter, and treatment with the 100 μM bezafibrate activated the reporter gene only weakly. Thus, at a concentration of 10 μM, bezafibrate can be used as a specific activator of rPPARα.
14 L-165041 compound has been recently identified as a human PPARβ agonist (32) . In order to characterize its activity profile on rPPARs, we tested this compound in the reporter gene assay in HeLa cells. In cells treated with 5 and 10 μM L-165041, there was only a small increase in PPARα mediated transcription of the reporter gene, indicating a weak effect of the compound on this isotype (Fig. 5B) . After a similar treatment, PPARβ-dependent activity of the reporter gene increased dramatically above its basal level (Fig. 5B) . This strong activation contrasts with the absence of background activity of rPPARβ and provide strong evidence for the high L-165041 responsiveness of this isotype. We therefore used this compound as a PPARβ activator on the aggregates. (Table 1) . Therefore, we conclude that treatment with the two activators did not modify the neuron and glial cell parameters and did not have general cytotoxic effects on the aggregates. This also suggested that the marker enzymes were probably not regulated by either PPAR.
Effect of bezafibrate and L-165041 on the aggregates:
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Acyl-CoA synthetase 2 is a target gene of PPARβ in reaggregated brain cell cultures: Specific activators or ligands of PPARα and PPARγ have been successfully used to identify their target genes. Therefore, it was reasonable to expect an effect of L-165041 on ACS2 expression if it was a target gene of PPARβ. Treatment of differentiated aggregates for 24 h with bezafibrate had no effect on either the ACS mRNAs or PPARβ mRNA (Fig. 6A) . However, a similar treatment of the aggregates with 5 and 10 μM L-165041 increased the ACS2 mRNA levels significantly (2.4 and 3 fold), but did not affect the ACS1 and 3 mRNAs (Fig. 6B) . We conclude that ACS2 is a target gene (35;36) . Therefore, the observations made in this model can be considered to reflect the in vivo situation. Since these aggregates were analyzed between 2 to 49 days, this study covers a period of time corresponding to the development of the brain from 18 day embryo to about six weeks postnatal period.
PPARs in the aggregates:
The differential expression of PPARs in the aggregates taken together with their cell type-specific expression pattern suggest that the neurons contain a low level of PPARα and a high level of PPARβ, whereas the glia contain a low level of both PPARs. This is in concert with the expression of PPARα and β in monolayer cultures of neonatal neurons (37) .
However, in astrocyte enriched monolayer cultures, it was observed that PPARβ mRNA levels were 18 higher than those of PPARα mRNA. Furthermore, in both neuron and astrocyte-enriched monolayer cultures, very low level of PPARγ was present (37) . It has also been reported that PPARβ was abundant in monolayer cultures enriched for oligodendrocytes but present only at low levels in primary astrocyte cultures (38) . Our in situ hybridization results indicate that in the aggregates PPARβ is present at a low level in both these cell types. These differences in PPAR expression between monolayer and aggregate cultures most likely reflect effects of these two modes of culture on gene expression.
The general differential expression of PPAR mRNAs in d49 aggregates (representative of the 6 weeks old rat brain) is consistent with that observed in the adult rodent (14;17;39) and human (40) brain in vivo. Furthermore, the cell type-specific expression of PPARβ in these aggregates is also consistent with that found in the rat brain (16;17) . Thus, PPARβ expression in the aggregates has more similarities with that in vivo than in monolayer cultures. This confirms that reaggregated cultures provide a better model to study the biological role of this PPAR isotype.
Acyl CoA synthetases in the aggregates:
The differential expression of ACSs in the aggregates, with ACS2 and 3 being abundant and ACS1 at a very low level, is consistent with that observed in the developing postnatal rodent brain (22;41) . Since the cell type-specific expression of ACS1, 2 and 3 mRNAs has not been studied in vivo, we analyzed the distribution of these mRNAs in the aggregates and found that ACS1 mRNA is localized mainly in the astrocytes and ACS2 mRNA in astrocytes and neurons. These expression patterns of ACS1 and ACS2 correlate well with PPARα and PPARβ expression, respectively. ACS3 mRNA was present in most cells of the aggregates, a pattern of expression quite different from that of PPARα or β. The similarity in the ACS2 and PPARβ expression patterns identified the former as the product of a potential target gene of the latter. We could confirm this in the differentiated aggregates, which have a high level of PPARβ, using an activator that exhibited a preference for this PPAR isotype.
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Activators of PPARβ: One of the key issues in analyzing PPARβ function is that of the availability of PPAR isotype selective ligands. All compounds that have been reported to activate PPARβ so far in various types of assays are also active on PPARα (7;14;27;42-44) . Species differences in PPAR ligand affinity is another factor that needs to be taken into account. For example, bezafibrate was identified as a ligand for xPPARβ (27) , but in reporter gene assay in HeLa cells, we found that bezafibrate was an activator of rPPARα but not of rPPARβ. In the same type of assay, L-165041 preferentially activated rPPARβ, which enabled us to identify ACS2 as the first target gene of this isotype.
ACS2 as a PPARβ target gene:
In this study we provide evidence that ACS2 is a target gene of 
